Precision Medicine in Oncology®

The FDA has granted a breakthrough therapy designation to the FGFR inhibitor futibatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma that harbors FGFR2 gene rearrangements, including fusions.

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

Gilteritinib was found to result in a significant improvement in overall survival when used in patients with FLT3-mutated, relapsed/refractory acute myeloid leukemia, meeting the primary end point of the confirmatory phase 3 COMMODORE trial in China.

Osimertinib (Tagrisso) showcased encouraging efficacy and acceptable safety in patients with EGFR-positive, advanced non–small cell lung cancer. according to real-world findings from an observational, multicenter study.

Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.

The fatty acid synthase inhibition caused by AZ12756122 could represent a promising therapeutic alternative to overcome resistance to EGFR TKIs because of the synergistic interaction that it has with osimertinib and its ability to reduce cancer stem cell properties in EGFR-mutant non–small cell lung cancer cell models.

The FDA has granted 2 breakthrough device designations to cover new intended uses of the Signatera molecular residual disease test developed by Natera, Inc.

Although Ki-67 is a commonly used measure of cellular proliferation in breast cancer tissue, its utility as a biomarker for helping to guide therapy decisions has been clouded by technical and clinical questions.

Circulating tumor DNA is working to transform care in colorectal cancer and beyond and positivity is actionable at this time.

Dr. Spira discusses the historical challenges of targeting KRAS, key findings from the phase 2 CodeBreaK 100 trial with sotorasib in KRAS G12C-mutant solid tumors, and the next steps of development for KRAS inhibitors in oncology.

Janakiraman Subramanian, MD, discusses the depth and durability of responses that have been reported with selpercatinib and pralsetinib, as well as ongoing research focused on improving outcomes and overcoming resistance mechanisms in RET fusion–positive NSCLC.

Lara A. Kujtan, MD, discusses the data that support the current utility of osimertinib in EGFR-mutant NSCLC and where else it is currently being explored.

The FDA has granted a fast track designation to poziotinib for use in previously treated patients with HER2 exon 20 mutations.

Dr. Levy discusses key research efforts with targeted therapies for patients with lung cancer who harbor NTRK, KRAS, and HER2 aberrations.

Melissa L. Johnson, MD, discusses the implications of recent advances made in the development of oncogenetargeted agents in non–small cell lung cancer.

Atrayee Basu-Mallick, MD, discusses the emerging role of ctDNA as a predictive biomarker in early-stage CRC and the growing importance of molecular testing in the advanced-stage setting.

The FDA has approved the VENTANA ALK CDx assay as a companion diagnostic to identify patients with ALK-positive non–small cell lung cancer who are eligible to receive treatment with lorlatinib.

Ibrutinib as a frontline treatment led to sustained efficacy and impressive 4-year progression-free and overall survival rates in patients with chronic lymphocytic leukemia who have TP53 aberrations.

Poziotinib, when given at a daily dose of 16 mg, was found to demonstrate clinically meaningful activity when used in treatment-naïve patients with metastatic non–small cell lung cancer who harbor EGFR exon 20 mutations.

John V. Heymach, MD, PhD, discusses the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.

The FDA has expanded the indication for lorlatinib to include the frontline treatment of patients with ALK-positive non–small cell lung cancer.

KRAS has topped the most wanted list of therapeutic targets in oncology for decades, but it has resolutely resisted all efforts, garnering it a reputation as undruggable.

In our exclusive interview, Paul K. Paik, MD, provides perspective on the FDA approval of tepotinib in MET exon 14-altered metastatic non–small cell lung cancer.

A supplemental new drug application has been submitted to the FDA for ivosidenib tablets as a potential therapeutic option for patients with previously treated, IDH1-mutated cholangiocarcinoma.

Jason Zhu, MD, discusses several approaches under exploration in the treatment of patients with previously treated, locally advanced, or metastatic urothelial carcinoma.